Alembic Pharmaceuticals announced that it has received final approval from the US Food Drug Administration USFDA for its Abbreviated New Drug Application ANDA for Mesalamine Extended-Release Capsules USP 0375 g The approved ANDA is therapeutically equivalent to the reference listed drug product RLD Apriso Extended-Release Capsules 0375 g of Salix Pharmaceuticals Inc Salix Mesalamine Extended-Release Capsules are indicated for the maintenance of remission of ulcerative colitis in adults Mesalamine Extended-Release Capsules USP 0375 g have an estimated market size of US$ 133 million for twelve months ending June 2022 according to IQVIA Alembic has a cumulative total of 174 ANDA approvals 150 final approvals and 24 tentative approvals from USFDA
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
